From ‘Test-tube Baby’ to ‘In Vitro Fertilization’? : the Changes of Media Report on New Science and Technology in the 1970~1980 Korea

2021 ◽  
Vol 136 ◽  
pp. 462-496
Author(s):  
Se-Kwon Jeong
Keyword(s):  
In Vitro Fertilization ◽  
Science And Technology ◽  
Test Tube ◽  
Media Report ◽  
Vitro Fertilization ◽  
New Science

Clinical biochemistry of assisted conception

2009 ◽  
Vol 46 (3) ◽  
pp. 197-204
Author(s):  
Rajeev Srivastava ◽  
Vanessa Kay
Keyword(s):  
In Vitro Fertilization ◽  
Clinical Biochemistry ◽  
Intrauterine Insemination ◽  
Test Tube ◽  
Fertility Treatment ◽  
Assisted Conception ◽  
Eligibility Criteria ◽  
Vitro Fertilization

Assisted reproductive technology has shown rapid advancement since the birth of the first ‘test-tube’ baby in Oldham, UK, in 1978. Since April 2005, women between the ages of 23 and 39, who meet the described eligibility criteria, are able to get one free in vitro fertilization cycle funded by the National Health Service. Private treatment costs anything from £4000 to £8000 for a single cycle of treatment. Almost 15% of the couples in UK are affected by fertility problems and undergo detailed investigations before being offered assisted conception. Assisted reproduction is the collective name for treatments designed to lead to conception by means other than sexual intercourse. These include intrauterine insemination, in vitro fertilization, intracytoplasmic sperm injection and gamete donation. This review is intended to summarize the principles of assisted conception and examine the role of the biochemistry laboratory in: (A) the diagnosis and subsequent management of ovulatory disorders; (B) assessing ovarian reserve before initiating fertility treatment and (C) monitoring fertility treatment. It touches on the screening of potential gamete donors and follow-up of children born after assisted conception. This article was prepared at the invitation of the Clinical Sciences Reviews Committee of the Association of Clinical Biochemistry.

Comparing Two Density Methods of Semen Preparation in Human Ejaculates

2021 ◽  
pp. 938-942
Author(s):  
Ram Dayal ◽  
Sumer Singh ◽  
Prabhat Kumar ◽  
Kamla Singh
Keyword(s):  
In Vitro Fertilization ◽  
Density Gradient ◽  
Semen Quality ◽  
Intrauterine Insemination ◽  
Sperm Concentration ◽  
Test Tube ◽  
Human Beings ◽  
Vitro Fertilization ◽  
Density Methods

Test tube baby is always a fascinating field of human reproductive biological science playing an important role in treating infertility. Poor semen quality is the major cause of infertility in human beings. Preparation of semen samples for intrauterine insemination (IUI) or in-vitro fertilization (IVF) is a key point in the success of test-tube embryo production. The study compared two different methods of semen preparation viz. double density gradient (DDG) and single density gradient (SDG) in patients seeking IUI / IVF treatment with their consent and permission of the hospital. Semen ejaculate from patients (n=100) was divided equally into two equal volume parts. One half of each sample was treated with DDG and another half with the SDG method of semen preparation. Results showed that sperm concentration was significantly higher (P>0.05) in SDG compared to DDG treated samples which were 58.65±181 and 49.89±180 Million/ml, respectively. Sperm motility of type-a and type-b both were significantly higher (P>0.05) in SDG compared to DDG treated samples which were 91.85± 3.15 and 68.85 ± 26.15. It is concluded that the single density gradient method is better than the double density gradient for semen ejaculates preparation during the treatment of male infertility using the in-vitro fertilization technique.

Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article

2020 ◽  
Author(s):  
Dariush D. FARHUD ◽  
Shaghayegh ZOKAEI ◽  
Mohammad KEYKHAEI ◽  
Marjan ZARIF YEGANEH
Keyword(s):  
Ovarian Cancer ◽  
In Vitro Fertilization ◽  
Clomiphene Citrate ◽  
Test Tube ◽  
Duration Of Treatment ◽  
Vitro Fertilization ◽  
Ovarian Hyper Stimulation Syndrome ◽  
History Of ◽  
High Doses

Background: In-vitro fertilization (IVF) has been very popular since the birth of the first “test-tube” baby. This method is the last hope and the most serious solution for couples with infertility problems. Although childbearing is a concern of many couples, it must always be noted that any method can also have disadvantages. Thus, many studies have been done on the problems encountered by this method. vantages. Thus, many studies have been done on the problems encountered by this method. Methods: We searched for relevant articles in Pub Med, Springer, Elsevier, and Google Scholar databases, and studied more than 70 papers. Keywords used included ovarian cancer, in vitro fertilization, gonadotropin hormone, clomiphene citrate, and infertility. Results: Due to the large number of studies, high doses of the ovulation-stimulating drugs and their repeated use in this method can increase the risk of the ovarian hyper stimulation syndrome (OHSS), and ovarian cysts, which can lead to ovarian cancer. Also, an increase in the risk of developing ovarian cancer can be due to the increased duration of treatment for up to 12 months and the high doses of medications that are followed by defecation and failure of this treatment. Conclusion: Due to the increase in the rates of infertility treatments and the incidence of gynecological cancers, especially ovarian cancer, this method need to be used with caution. IVF clients and candidates should be informed about potential future risks. People should be evaluated genetically for their history of ovarian cancer and be more aware of the importance of “Personalized medicine”.    

The “Brave New Baby” and the Law: Fashioning Remedies for the Victims of In Vitro Fertilization

1978 ◽  
Vol 4 (3) ◽  
pp. 317-336
Author(s):  
Mark E. Cohen
Keyword(s):  
In Vitro Fertilization ◽  
Civil Liability ◽  
Test Tube ◽  
Federal Regulation ◽  
Vitro Fertilization ◽  
Legal Problems ◽  
The Law ◽  
Hazardous Use

AbstractThe birth of the world's first “test-tube baby,” a child conceived by in vitro fertilization (IVF), raises serious medical, ethical, and legal problems. This Note explores the present controversy over the use of IVF and advocates federal regulation of the technique. Furthermore, this Note argues that, in order to deter unduly hazardous use of IVF and to compensate its victims, an experimenter should be subject to civil liability for either negligent, or willful and nonconsensual, destruction of an IVF conceptus, and held strictly liable when an IVF child is born with severe defects that are attributable to the use of the technique.

Predictive Model for Live Birth at 12 Months After Starting In-Vitro Fertilization Treatment

MedPharmRes ◽  
2018 ◽  
Vol 2 (2) ◽  
pp. 5-20
Author(s):  
Vu Ho ◽  
Toan Pham ◽  
Tuong Ho ◽  
Lan Vuong
Keyword(s):  
In Vitro Fertilization ◽  
Live Birth ◽  
Cox Regression ◽  
Financial Burden ◽  
Oocyte Retrieval ◽  
Operating Characteristics ◽  
Vitro Fertilization ◽  
Cox Regression Analysis ◽  
Significant Difference

IVF carries a considerable physical, emotional and financial burden. Therefore, it would be useful to be able to predict the likelihood of success for each couple. The aim of this retrospective cohort study was to develop a prediction model to estimate the probability of a live birth at 12 months after one completed IVF cycle (all fresh and frozen embryo transfers from the same oocyte retrieval). We analyzed data collected from 2600 women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) at a single center in Vietnam between April 2014 and December 2015. All patients received gonadotropin-releasing hormone (GnRH) antagonist stimulation, followed by fresh and/or frozen embryo transfer (FET) on Day 3. Using Cox regression analysis, five predictive factors were identified: female age, total dose of recombinant follicle stimulating hormone used, type of trigger, fresh or FET during the first transfer, and number of subsequent FET after the first transfer. The area under the receiver operating characteristics curve for the final model was 0.63 (95% confidence interval [CI] 0.60‒0.65) and 0.60 (95% CI 0.57‒0.63) for the validation cohort. There was no significant difference between the predicted and observed probabilities of live birth (Hosmer-Lemeshow test, p > 0.05). The model developed had similar discrimination to existing models and could be implemented in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document